There was no significant difference between NOTCH1-mutated and NOTCH1-wild T-ALL patients as well as NOTCH1-heterodimerization versus NOTCH1-PEST mutated patients in terms of measurable residual disease (MRD), relapse-free survival (RFS) and/or overall survival (OS). The gene discussed is NOTCH1; the disease is acute lymphoblastic leukemia.